TRUQAP (capivasertib)
TRUQAP (capivasertib) from AstraZeneca is an AKT inhibitor used in hormone receptor–positive breast cancer.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TRUQAP. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where TRUQAP is tied to a specific indication and biomarker definition.
No indication-specific companion diagnostic approvals are currently mapped for this therapy.
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TRUQAP.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TRUQAP for eligible patients.